Dose-intensive approaches to ovarian cancer.
Increasing the total dose or the dose intensity of platinum does not improve survival in women with ovarian cancer. High-dose chemotherapy with hematologic support has not been shown to be more effective than standard-dose chemotherapy. Regional dose intensity, through intraperitoneal chemotherapy, may have a role in the treatment of advanced ovarian cancer. Further studies are needed to identify the optimal combination of agents, in addition to a platinum and a taxane, to be used in primary therapy for ovarian cancer.
Lambrou
N
N
Department of Gynecology and Obstetrics, The Johns Hopkins Hospital, Phipps 248, 600 North Wolfe Street, Baltimore, MD 21287, USA.
Trimble
E L
EL
D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004305:Dose-Response Relationship, Drug; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011379:Prognosis; D016019:Survival Analysis; D019772:Topotecan / Q000008:administration & dosage; D000093542:Gemcitabine
D018943:Anthracyclines; D003841:Deoxycytidine; D005047:Etoposide; D019772:Topotecan; D003520:Cyclophosphamide; D000093542:Gemcitabine